浙江医药(600216.SH)：前三季度净利润9.33亿元，同比增长9.83%

Core Viewpoint - Zhejiang Medicine (600216.SH) reported a decline in total operating revenue for the first three quarters of 2025, while net profit attributable to shareholders increased, indicating mixed financial performance [1] Financial Performance - Total operating revenue for the first three quarters reached 6.695 billion, a year-on-year decrease of 5.87% [1] - Net profit attributable to shareholders was 933 million, reflecting a year-on-year increase of 9.83% [1] - Basic earnings per share stood at 0.97 yuan [1]